BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) will host a conference call on June 12, 2007 at 11:00 am EDT to review interim results from its Phase I clinical trial of sapacitabine (CYC682) in patients with advanced leukemias or myelodysplastic syndromes (MDS). Spiro Rombotis, President and CEO, and Dr. Judy Chiao, VP of Clinical Development and Regulatory Affairs of Cyclacel, will be joined by the study’s principal investigator, Dr. Hagop Kantarjian, Professor of Medicine and Chairman of the Leukemia Department at The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston.
